Categories
Health

Pfizer at-home Covid capsule could possibly be out there by year-end, CEO Albert Bourla says

Pfizer’s experimental oral drug to treat Covid-19 at the first sign of illness could be available by the end of the year, CEO Albert Bourla told CNBC on Tuesday.

The company, which developed the first approved Covid-19 vaccine in the US with the German drug manufacturer BioNTech, started an early clinical study in March testing a new antiviral therapy for Covid. The drug belongs to a class of drugs called protease inhibitors, and it works by blocking an enzyme that the virus needs to replicate in human cells.

Protease inhibitors are used to treat other viral pathogens such as HIV and hepatitis C.

If the clinical trials go well and the Food and Drug Administration approves it, the drug could be distributed in the US by the end of the year, Bourla told CNBC’s Squawk Box.

Health experts say the orally taken drug could be a game changer as people newly infected with the virus could use it outside of hospitals. The researchers hope the drugs will prevent the disease from getting worse and prevent hospital stays.

In addition to the drug, Pfizer is also testing its vaccine in 6-month-old to 11-year-old children. Vaccinating children is critical to ending the pandemic, say public health officials and infectious disease experts.

Earlier this month, the company asked the FDA to extend their vaccine approval to teenagers ages 12-15 after a study found the shot was 100% effective.

Bourla told CNBC on Tuesday that he was “very optimistic” that the FDA would approve the use of the shot in teenagers.

Categories
Business

J&J requested Pfizer, Moderna to assist research blood clots however they declined: WSJ

A person walks past a sign that reads “The vaccine is our best shot against COVID-19” on the Upper West Side amid the coronavirus pandemic in New York City on March 30, 2021.

Noam Galai | Getty Images

Johnson & Johnson has privately asked Covid-19 vaccine competitors Pfizer and Moderna to participate in a study examining the potential risk of blood clots. The companies refused, however, the Wall Street Journal reported on Friday, citing people familiar with the matter.

Pfizer and Moderna executives said their vaccines were safe and they didn’t see the need to redouble efforts by regulators and companies already addressing the rare blood clot problem, the journal’s report said.

Only AstraZeneca, whose vaccine raised regulatory concerns about blood clots, agreed to join the effort, the Journal said.

CNBC has asked the four companies to comment.

On Tuesday, the Food and Drug Administration and Centers for Disease Control and Prevention advised states to temporarily suspend use of J & J’s vaccine “out of caution” after six women developed a rare but potentially life-threatening bleeding disorder Dead and one left in critical condition.

The women developed a condition known as cerebral venous sinus thrombosis (CVST) within about two weeks of receiving the shot, US health officials told reporters. CVST is a rare form of stroke that occurs when a blood clot forms in the venous sinuses of the brain. It can eventually leak blood into the brain tissue and cause bleeding.

A CDC panel on Wednesday decided to postpone a decision on J & J’s vaccine use while officials investigate the cases.

Read the full Wall Street Journal report here.

Categories
Health

Pfizer CEO says third Covid vaccine dose doubtless wanted inside 12 months

President Joe Biden listens as Pfizer CEO Albert Bourla speaks at the Pfizer Kalamazoo manufacturing facility in Portage, Michigan on February 19, 2021.

Brendan Smialowski | AFP | Getty Images

Albert Bourla, CEO of Pfizer, said people “likely” will need a booster dose of a Covid-19 vaccine within 12 months of being fully vaccinated. His comments were posted on Thursday but recorded on April 1st.

Bourla said it was possible that people would need to be vaccinated against the coronavirus annually.

“A likely scenario is that a third dose is likely to be needed, somewhere between six and twelve months, and there will be an annual revaccination from there, but all of this needs to be confirmed. And again the variants will play a key role,” said he Bertha Coombs of CNBC during an event with CVS Health.

“It is extremely important to suppress the pool of people who may be susceptible to the virus,” Bourla said.

The comment comes after Johnson & Johnson CEO Alex Gorsky told CNBC in February that people may need to be vaccinated against Covid-19 annually, just like seasonal flu shots.

Researchers still don’t know how long protection against the virus will last once someone has been fully vaccinated.

Pfizer said earlier this month that up to six months after the second dose, its Covid-19 vaccine was more than 91% effective against the coronavirus and more than 95% effective against serious illnesses. Moderna’s vaccine, which uses technology similar to Pfizer, was also shown to be highly effective after six months.

Pfizer’s data was based on more than 12,000 vaccinated participants. However, researchers say more data is needed to determine if protection continues after six months.

David Kessler, the Biden government’s chief science officer for Covid Response, said earlier Thursday that Americans should expect booster vaccinations to protect against coronavirus variants.

Kessler told US lawmakers that currently approved vaccines offer high levels of protection, but that new variants may “question” the effectiveness of the shots.

“We don’t know everything right now,” he told the House Select subcommittee on the coronavirus crisis.

“We are investigating the durability of the antibody response,” he said. “It seems strong, but it’s wearing off a bit and no doubt the variants are challenging … they make these vaccines work harder. So I think we should, for planning purposes, for planning purposes only, expect us to possibly need to increase. “”

In February, Pfizer and BioNTech announced that they were testing a third dose of their Covid-19 vaccine to better understand the immune response against new variants of the virus.

At the end of last month, the National Institutes of Health began testing a new Covid vaccine from Moderna, in addition to the existing one, which is intended to protect against a problematic variant first found in South Africa.

Moderna CEO Stephane Bancel told CNBC on Wednesday that the company is hoping to have a booster shot for its two-dose vaccine in the fall.

Categories
World News

European Union Guarantees Additional Covid-19 Vaccine Doses From Pfizer

The European Union will receive an additional 50 million doses of the coronavirus vaccine developed by Pfizer and BioNTech this month, accelerating its efforts to accelerate vaccination amid difficulties with vaccines developed by AstraZeneca and Johnson & Johnson.

The announcement by Ursula von der Leyen, President of the European Commission, is part of the European Union’s tough pivot for mRNA vaccines like Pfizer, which is basing its future coronavirus response on it.

The measures come a day after Johnson & Johnson suspended rollout of its vaccine in the European Union and the block continued to suffer from the restrictions of the AstraZeneca vaccine after reports of extremely rare but serious potential side effects from both.

The 27-nation bloc has also started negotiations with Pfizer for the delivery of 1.8 billion new doses of vaccine – including booster shots to extend immunity and new vaccines to combat emerging variants – in 2022 and 2023, Ms. von der Leyen said .

In another setback for AstraZeneca, Denmark became the first country to permanently stop administering the company’s vaccine on Wednesday. The potential side effects are significant enough to do so, given that the pandemic was under control and two other vaccines could be used. from Pfizer and Moderna.

The European Union has not canceled its existing orders for the AstraZeneca and Johnson & Johnson vaccines, but has signaled that they will no longer be placing.

The European Medicines Agency, the bloc’s top medicine agency, goes on to say that the benefits of the AstraZeneca vaccine far outweigh the risks of a dangerous but extremely rare blood disorder for most people. On Wednesday, the agency said it was accelerating its investigation of “very rare cases of unusual blood clots” in recipients of the Johnson & Johnson vaccine and is expected to issue a recommendation next week.

During the ongoing evaluation, the Agency reiterated its view that it will reap the benefits Vaccine also outweigh the risks.

The European Union’s move away from AstraZeneca follows troubled months as relations between the company and the bloc deteriorated due to late deliveries and unpredictable deliveries. And since then, concerns about possible side effects have heightened skepticism about vaccines, which was already dangerously high in Europe.

These problems have contributed to the fact that Europe has lagged seriously behind vaccination campaigns in the US and UK. The block hopes the new Pfizer broadcasts will help it catch up and meet its goal of fully vaccinating 70 percent of its adult population, roughly 255 million people, by the end of the summer.

Pfizer’s commitment to move ahead with deliveries of the 50 million cans originally planned for the end of the year means the company will deliver a total of 250 million cans to the block by the end of June.

“We now have to concentrate on technologies that have proven themselves: mRNA vaccines are a clear example of this,” said Ms. von der Leyen.

Monika Pronczuk contributed to the reporting.

Categories
Business

Pfizer CEO says firm can ship 10% extra doses to the U.S. by the tip of Might than beforehand agreed

The bottles for the Pfizer BioNTech COVID-19 vaccine can be prepared prior to the opening of a mass vaccination site in Queens, New York City on February 24, 2021.

Seth Little | Pool | Reuters

Albert Bourla, CEO of Pfizer, said Tuesday that his company had ramped up production of its two-shot coronavirus vaccine and could ship a total of 300 million doses to the U.S. ahead of schedule.

According to Bourla, Pfizer can deliver 10% more cans to the US by the end of May than previously agreed. The company will be able to bring the full 300 million into the US two weeks early, he said.

The announcement came when dozen of states temporarily stopped giving Johnson & Johnson’s single-dose Covid vaccine after the Food and Drug Administration recommended it after six women in the United States developed a rare bleeding disorder in which one woman died and another died in critical condition.

Some states, like New York, said they would use Pfizer’s vaccine instead of the J&J shot for appointments that were already scheduled.

President Joe Biden set a goal last month to get enough Americans vaccinated in time for them to safely gather in small groups for July 4th. He also vowed that every adult in the US would have access to the vaccine by the end of May.

This is the latest news. Please try again.

Categories
Business

Covid variant from South Africa was capable of ‘break by means of’ Pfizer vaccine in Israeli research

An Israeli health worker from Maccabi Healthcare Services prepares to deliver a dose of the Pfizer BioNtech vaccine in Tel Aviv on February 24, 2021.

Jack Guez | AFP | Getty Images

The coronavirus variant, first discovered in South Africa, may evade some of the protection provided by the Pfizer BioNTech vaccine, according to a new Israeli study that has not yet been peer-reviewed.

Researchers from Tel Aviv University and Clalit, the largest health organization in Israel, examined nearly 400 people who had tested positive for Covid-19 after receiving at least one dose of the vaccine. They compared it to the same number of people who were infected and not vaccinated.

The researchers found that the prevalence of the South African variant known as B.1.351 was about eight times higher in patients who received two doses of the vaccine than in those who were not vaccinated. The data, released online over the weekend, suggest that B.1.351 may “break through” the vaccine’s protection better than the original strain, the researchers in the study wrote.

“Based on patterns in the general population, we would have expected only one case of the South African variant, but we saw eight,” Professor Adi Stern, who led the research, told The Times of Israel. “We can say it’s less effective, but more research is needed to see exactly how much.”

CNBC asked Pfizer to comment on the study.

The new data comes as public health officials are increasingly concerned that highly contagious variants, studies have shown can reduce the effectiveness of vaccines, could slow global advances in the pandemic.

Last month, CDC Director Dr. Rochelle Walensky issued a terrible warning, telling reporters that she feared the United States was facing “impending doom” as variants spread and daily Covid-19 cases rise again, threatening to move more people to the US send hospital.

“I’m going to stop here, I’m going to lose the script, and I’m going to think about the recurring feeling I have before the impending doom,” she said on March 29, so much promise and potential where we are and so much reason to Hope, but right now I’m scared. “

Israel launched its national vaccination campaign in December, prioritizing people aged 60 and over, healthcare workers, and people with comorbid illnesses. By February, it was the world leader in vaccinations, vaccinating millions of its citizens against the virus.

In January, Pfizer and the Israeli Ministry of Health signed a collaboration agreement to monitor the real effects of its vaccine.

The researchers found that the study’s main limitation was sample size. B.1,351 only made up about 1% of all Covid-19 cases, they said. B.1.1.7, the variant first identified in Great Britain, is more common.

As the variants spread, drug manufacturers tested whether a third dose would offer more protection.

In February, Pfizer and BioNTech announced that they were testing a third dose of their Covid-19 vaccine to better understand the immune response against new variants of the virus.

Categories
Health

Fauci says two photographs of Pfizer or Moderna are higher than one

46-year-old Edith Arangoitia (who came to accompany her older mother) was born on February 16, 2021 by Dr. Galen Harnden in La Colaborativa in Chelsea, Massachusetts, was vaccinated with the Pfizer-BioNTech Covid-19 vaccine.

Joseph Precious | AFP | Getty Images

The Chief Medical Officer of the White House, Dr. Anthony Fauci said Monday that Americans should continue to receive two doses of the Pfizer and Moderna Covid-19 vaccines, although a recent study in the US showed the shots were highly effective after just one dose.

A study by the Centers for Disease Control and Prevention published last week found that a single dose of the Covid-19 vaccine from Pfizer or Moderna was 80% effective in preventing coronavirus infections in healthcare workers and other key workers. Two doses are better than one, federal health officials said, adding that the vaccines’ effectiveness rose to 90% two weeks after the second dose.

While the 80% figure was good news, Fauci said Monday he was still concerned about the length of protection after a single dose, particularly the emergence of highly contagious variants that have shown they can evade the vaccines’ protection .

“If you look at the level of protection after a dose, you can say it’s 80%, but it’s a little weak 80%,” Fauci said during a White House press conference on the pandemic. “If you leave it at one dose, how long will it take?”

Highly infectious Covid-19 variants that have shown some resistance to vaccines also pose a challenge, Fauci said. “You’re in a weak zone if you don’t get the full effect of two doses,” he said.

Fauci’s comments come as some health experts and public health officials argue that the U.S. should prefer to give Americans just one dose of the vaccines before moving on to a second dose, accelerating the pace of vaccinations across the country.

Unlike the Johnson & Johnson vaccine, which requires one dose, the Pfizer and Moderna vaccines require two vaccinations three to four weeks apart. In the UK, health officials decided to increase the time between the first and second dose to 12 weeks to speed up vaccinations.

Fauci has said repeatedly over the past few months that the US should stick to the two-dose regime.

Dr. Paul Offit, a voting member of the FDA’s Vaccines and Related Biological Products Advisory Committee who reviewed both Pfizer and Moderna’s vaccines for emergency approval, told CNBC last week that studies showed immunity after the second dose actually appears to be “more permanent”, meaning that protection can last longer.

The two-dose vaccination schedule also produces ten times the amount of neutralizing antibodies, which play an important role in fighting the virus, from the first dose to the second, Offit told CNBC.

Second, and more importantly, after the second dose, scientists also discovered what are known as T cells, another important part of the immune response that usually provides longer-lasting immunity, he said.

Fauci said Monday he “respects” the case for a one-dose strategy, but added that the US currently has enough doses to provide Americans with the first and second dose. “Although we always stay open, we consider the route we are on to be the best route,” he said.

Categories
Health

Pfizer says shot is 100% efficient in children ages 12 to 15

A nurse, Cindy Mendez, wearing a protective mask, holds a syringe containing a dose of Pfizer-BioNTech COVID-19 vaccine during the coronavirus disease (COVID-19) pandemic at NYC Health + Hospitals Harlem Hospital in the Manhattan neighborhood of New York City. New York, February 25, 2021.

Jeenah Moon | Reuters

Pfizer said on Wednesday that its Covid-19 vaccine was 100% effective in a study in adolescents ages 12-15.

Albert Bourla, CEO of Pfizer, said the company hoped to submit the new data on the vaccine, which was being developed in partnership with German drug maker BioNTech, “as soon as possible” to the Food and Drug Administration and other regulatory agencies that children in the age group can get vaccinated before the next school year.

“We share the urgency to expand our vaccine approval to younger populations and are encouraged by clinical trial data from adolescents 12-15 years of age,” Bourla said in a press release.

The study enrolled 2,260 participants in the United States. 18 confirmed Covid-19 infections were observed in the placebo group and no confirmed infections were observed in the group that received the vaccine, the company said. This resulted in a vaccine effectiveness of 100%. The shot is also well tolerated, with side effects generally the same as in adults.

The company also said the vaccine produced a “robust” antibody response in children that outperformed that in a previous study of 16-25 year olds.

Vaccinating children is critical to ending the pandemic, say public health officials and infectious disease experts. The nation is unlikely to achieve herd immunity – if enough people in a given community have antibodies to a given disease – until children can be vaccinated, experts say.

According to the government, children make up around 20% of the US population. According to experts, between 70% and 85% of the US population must be vaccinated against Covid to achieve herd immunity and some adults may refuse to get the shots.

Dr. Scott Gottlieb, a former FDA commissioner, said he expected it would take the U.S. agency about a month to review the new data. If the FDA process goes well, the vaccine could be available to children between the ages of 12 and 15 by the fall, he told CNBC’s Squawk Box.

Isaac Bogoch, an infectious disease specialist who served on various data and security monitoring bodies, described the results as “wonderful news”. This is a “big step forward” in protecting more people from the virus and making schools safer for children.

“We are talking about improving the safety of youth activities such as youth sports and art, as well as after-school activities for youth,” he said.

Pfizer’s vaccine has already been approved for use in the United States in people aged 16 and over. Clinical studies testing the vaccine in children whose immune systems may react differently than adults had yet to be completed.

The Chief Medical Officer of the White House, Dr. Anthony Fauci, speaking to a House committee earlier this month, said the U.S. could vaccinate older children against Covid-19 starting this fall, while elementary school-age children may get their shots early next year.

Moderna, which also has a US-approved vaccine, announced on March 16 that it has started testing its shot in children under the age of 12. Moderna started a study in December testing children ages 12-17.

Johnson & Johnson plans to test its single-shot vaccine in infants and even newborns after it was first tested in older children, according to the New York Times.

Pfizer announced last week that it had started a clinical trial testing its Covid-19 vaccine in healthy children aged 6 months to 11 years.

In the first phase of this study, the company will determine the preferred dosage level for three age groups – between 6 months and 2 years, 2 and 5 years, and between 5 and 11 years. The children will initially receive a dose of 10 micrograms of the vaccine before gradually moving to higher doses, according to the company. Participants also have the option of ingesting 3 micrograms doses.

Pfizer said Wednesday it plans to apply to the FDA for an amendment to its current emergency approval to include adolescents ages 12-15. All participants in the study will be monitored for two more years after their second dose, the company said.

Pfizer and BioNTech plan to submit the data for scientific review.

Categories
Business

CDC examine reveals single dose of Pfizer or Moderna Covid vaccines was 80% efficient

According to a new study by the Centers for Disease Control and Prevention of vaccinated health care workers, a single dose of the Covid-19 vaccine from Pfizer or Moderna was 80% effective in preventing coronavirus infections.

The effectiveness of the partial immunization was noted two weeks after the first dose, according to the CDC, which studied nearly 4,000 health care workers, first responders and frontline workers between December 14 and March 13, according to other key study staff, which began on Monday had no prior laboratory documentation of the Covid-19 infection.

Two doses are better than one, federal health officials said, adding that the vaccines’ effectiveness rose to 90% two weeks after the second dose.

“These results show that approved mRNA-COVID-19 vaccines in adults of working age effectively prevent SARS-CoV-2 infection under real conditions, regardless of symptom status,” wrote the US agency in the study. “The COVID-19 vaccination is recommended to all entitled persons.”

The new CDC results should back up arguments by some health experts and health officials that the US should give Americans only one dose of vaccines as a priority before moving on to a second dose, accelerating the pace of vaccination across the country.

The CDC results were released just minutes before the press conference by the agency’s director, Dr. Rochelle Walensky, the hospital also released as vaccinations nationwide expedite.

Unlike the Johnson & Johnson vaccine, which requires one dose, the Pfizer and Moderna vaccines require two vaccinations three to four weeks apart. The Chief Medical Officer of the White House, Dr. Anthony Fauci, has said repeatedly over the past few months that the US should stick to the two-dose regime.

Dr. Paul Offit, a voting member of the FDA’s Advisory Committee on Vaccines and Related Biological Products who reviewed both Pfizer’s and Moderna’s vaccines for emergency approval, said the CDC study was overall “good news” .

However, he said he feared people would now think a dose of the vaccines was “good enough” and would not return for a second shot. He said studies have shown that immunity actually appears to be “more permanent” after the second dose, meaning protection may last longer.

“The reason these are two-dose vaccines is because the second dose provides a titer of neutralizing antibodies, virus-specific neutralizing antibodies, that is nearly ten times greater than the first dose,” he told CNBC. Neutralizing antibodies play an important role in the defense of cells against the virus.

Second, and more importantly, scientists have also discovered what are known as T cells, another important part of the immune response that usually lasts longer Immunity, he said.

There are also still questions about the highly contagious variants and whether the vaccines protect mild to moderate forms of the disease, he said.

Of the 3,950 participants in the study, 2,479, or 62.8%, received both recommended doses, and 477, or 12.1%, received only one dose, according to the CDC. The infection rate among the vaccinated participants was 0.04 compared to 1.38 among the non-vaccinated participants.

The study was conducted in eight locations in the United States: Phoenix, Tucson, and other areas in Arizona; Miami, Florida; Duluth, Minnesota; Portland, Oregon; Temple, Texas; and Salt Lake City, Utah. The majority of the participants were female, white, and had no chronic illnesses, according to the CDC.

The study had limitations, the CDC said, adding that delays in deliveries could reduce virus detection sensitivity of Covid-19 tests.

Preliminary real-world vaccine efficacy results for both vaccines complement and expand on estimates of vaccine efficacy from other recent studies, the CDC said. A large study published in the New England Journal of Medicine in February found that Pfizer’s vaccine was 94% effective against symptomatic Covid.

Categories
Health

Pfizer Begins Testing Its Vaccine in Younger Kids

Pfizer has started testing its Covid-19 vaccine in children under the age of 12. This is an important step in reducing the pandemic. The first participants in the study, a pair of 9-year-old twin girls, were vaccinated on Wednesday at Duke University in North Carolina.

Results of the study are expected in the second half of the year, and the company hopes to vaccinate younger children early next year, said Sharon Castillo, a spokeswoman for the drug company.

Moderna is also starting testing its vaccine in children aged six months to 12 years. Both companies have tested their vaccines in children 12 years and older and expect these results in the next few weeks.

AstraZeneca began testing its vaccine in children six months and older last month. Johnson & Johnson has announced plans to extend the vaccine trials to young children after assessing performance in older children.

Immunizing children will help schools reopen and end the pandemic, said Dr. Emily Erbelding, an infectious disease doctor at the National Institutes of Health who oversees the testing of Covid-19 vaccines in specific populations.

An estimated 80 percent of the population may need to be vaccinated for the United States to achieve herd immunity, the threshold above which the coronavirus can no longer infect people. Some adults may refuse to be vaccinated, while others may not produce a robust immune response.

Children under the age of 18 make up about 23 percent of the US population. Even if the vast majority of adults choose vaccines, “herd immunity may be difficult to achieve without vaccinating children,” said Dr. Erbelding.

Pfizer originally announced that it would wait for data from older children before starting trials of its vaccine in children under the age of 12. “We were encouraged, however, by the data from the group of 12-15 year olds,” said Ms. Castillo, who did not elaborate on results so far.

Scientists will test three doses of the Pfizer vaccine – 10, 20, and 30 micrograms – in 144 children. Each dose is assessed first in children aged 5 to 11 years, then in children aged 2 to 4 years, and finally in the youngest group aged six months to 2 years.

After determining the most effective dose, the company will test the vaccine on 4,500 children. Approximately two-thirds of the participants are randomly selected to receive two doses 21 days apart. The remainder received two placebo injections of saline solution. The researchers will study the children’s immune response in blood drawn seven days after the second dose.

Updated

March 25, 2021, 2:39 p.m. ET

“It sounds like a good plan, and it’s exciting to see another Covid-19 vaccine drive studies in children,” said Dr. Kristin Oliver, pediatrician and vaccine expert at Mount Sinai Hospital in New York.

Dr. Oliver said that about half of the parents she sees in the office eagerly await vaccines and even volunteer their children for clinical trials, while the rest are skeptical because comparatively few children get seriously ill with coronavirus infection .

Both parent groups will benefit from knowing exactly how safe and effective the vaccines are in children, she said.

Children make up 13 percent of all reported cases in the United States. More than 3.3 million children tested positive for the virus, at least 13,000 were hospitalized and at least 260 died, noted Dr. Yvonne Maldonado, who represents the American Academy of Pediatrics on the Federal Advisory Board on Immunization Practices.

The figures do not fully capture the damage to the health of children. “We don’t know how a Covid infection will affect the long term,” said Dr. Maldonado.

Other vaccines have helped fight many terrible teething problems that can cause long-term complications. She added, “For some of us who have seen this, we don’t want to go back to that time.”

Children are often more responsive to vaccines than adults, and infants and young children in particular can have a high fever. All side effects are likely to appear soon after the shot, within the first week, and certainly within the first few weeks, experts have said.

Some vaccines are only tested on animals before being studied in children and must be carefully monitored for side effects.

“But that’s a little different because we’ve already had tens of millions of people with these vaccines,” said Dr. Maldonado. “So there is more confidence to give this vaccine to children.”

Some experts suggested that the Food and Drug Administration may need up to six months of safety data from studies in children before the Covid-19 vaccines are approved. However, a spokeswoman said the agency did not expect safety data to support approval of the vaccines for six months.

The Pfizer BioNTech vaccine is approved for children ages 16-18, and approval for that age group was based on just two months of safety data, she said.

Parents will want to know how the companies and the FDA plan to monitor and disclose the side effects of the vaccines and how long they will pursue study participants after the vaccines are approved, said Dr. Oliver.

“I think everyone has learned that,” she said. “The more transparent you can be, the better.”